Mark Muldowney is head of technology at Sterling Pharma Solutions.

Mark Muldowney 

The advantages that enzymes have as biocatalysts are well known within the pharmaceutical manufacturing industry, not least that they can give excellent specificity and yields, and even facilitate reactions that are difficult with chemical catalysts. Their credentials towards improving sustainability are also increasing the levels of interest for process development, as biocatalytic reactions can be more efficient in terms of solvent and material use.

Pharmaceutical Technology’s October 2021 APIs, Excipients, and Manufacturing eBook

Read the article:
Seeking Economies of Scale for Biocatalysis

Mark Muldowney is head of technology, and innovation and Greg Holgate is biocatalysis chemist, both with Sterling Pharma Solutions.

When referring to this article, please cite it as M. Muldowney and G. Holgate, “Seeking Economies of Scale for Biocatalysis,” 

Pharmaceutical Technology APIs, Excipients, and Manufacturing 

Articles

New enzymes and protein engineering have advanced biocatalysis processing toward commercial acceptance. Technology and economic roadblocks must be overcome for the process to be widely embraced by pharma.